Insider Sales Cast a Shadow as Canopy Growth Waits on Washington Decree

Three Canopy Growth directors sold shares at ~92 cents each amid tax settlements. Stock down 15-17% YTD, near $1 threshold. US cannabis rescheduling by DEA remains key catalyst for unlocking $50B market potential.

Three Canopy Growth directors moved to reduce their holdings on 29 June, selling shares at roughly 92 US cents apiece. David Angelo Lazzarato, Theresa Yanofsky and Joseph Bayern all offloaded stock, a move the company framed as routine tax settlements on vested options. For a stock already trading near troubled waters, the optics could hardly be worse. The shares now change hands at around €0.87, having shed between 15% and 17% of their value since 1 January. That leaves the equity a long way from its 52-week peak of €2.00 and dangerously close to the critical US$1 threshold.

The real prize for the cannabis producer lies south of the Canadian border. The US market is forecast to reach US$50 billion by 2026, and Canopy Growth has built a holding company – Canopy USA – that already owns brands such as Wana, Jetty and Acreage Holdings, plus a strategic stake in TerrAscend. But without a rescheduling of marijuana at the federal level, those assets remain cordoned off from the parent’s balance sheet and cash flows. The DEA is currently reviewing whether to move cannabis from Schedule I to Schedule III, a shift that would slash punitive tax penalties under Section 280E and allow Canopy to fully consolidate its US operations. That outcome would unlock synergies, lower operating costs and let the company deploy its Canadian cultivation expertise across state lines.

Yet the path to that catalyst is clogged with risks. Any delay in Washington keeps the company in a regulatory straitjacket: Canopy holds only non-voting interests in Canopy USA and cannot book its profits or exert direct control. Meanwhile, the balance sheet remains strained. In August 2025 the management launched an at-the-market equity programme to raise up to US$200 million, earmarked for acquisitions and debt reduction. Each new share sold dilutes existing holders, and if the political breakthrough stalls, selling pressure could accelerate.

The operational picture is equally sobering. A recent quarterly report missed analyst expectations, and the company acknowledged material weaknesses in its internal financial controls – a disclosure that unnerves retail investors and makes the path to profitability more arduous. Competitors are not standing still. Tilray Brands has snapped up the digital health platform HelloMD, while TerrAscend is pursuing a reverse stock split to qualify for listing on a major US exchange. Canopy Growth, by contrast, finds itself fighting on multiple fronts with limited ammunition.

Chart watchers are now focused on the US$1 level. The stock has already visited its yearly low of 84 US cents, and a sustained break below the psychological dollar mark could trigger a fresh wave of selling. Until the DEA delivers its final verdict – the single most powerful catalyst on the horizon – the company’s fate hangs on a Washington timeline that has already frustrated investors. For now, Canopy Growth is playing a waiting game, one where the margin for error is razor-thin and the latest insider transactions only underscore the tension.